Mike:
The project is far from phase I. It's an interesting new project for GZMO, but I honestly believe that the way to play this going forward is to short ENMD.
Should gap down tomorrow and continue, relentlessly, for several days.
This, IMO, is the telling story.....
"Genzyme is the appropriate licensee for this compound," commented Donald
P. Lombardi, director, technology transfer, Children's Hospital, Boston.
"Genzyme possesses the manufacturing and commercialization expertise, the
technical and financial resources, and the willingness to make the needed
strategic commitment to develop this compound."
Children's has committed to being their own competitor.
Rick |
